SANTA MONICA, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. today announced that it has received an award from the Science and Technology Department of Zhejiang Province, one of the richest regions in China and known throughout the country for its focus on innovation. Aida was rewarded by the governmental authority because of its "clinical research and commercialization of Rh-Apo2L" as a "significant scientific and social developing project" recognized by the Science and Technology Department of Zhejiang Province. The Science and Technology Department of Zhejiang Province is the governmental administrative department for the entire science and technology industry in Zhejiang Province.
Mr. Jin Biao, Chairman of Aida Pharmaceuticals, stated, "We are very honored to have this major award bestowed on us by the Science and Technology Department of Zheijiang Province. The government has supported our efforts throughout Rh-Apo2L's development process." The award also includes a financial reward, totaling RMB1.2 million (US$164,982.47, as of January 2008).
About Aida Pharmaceuticals
Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. The Company has nine product lines including its main product, Etimicin Sulfate, the first antibiotic developed in China, which it manufactures and markets in powder, liquid and transfusion form. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995
With the exception of historical information, the matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Aida Pharmaceuticals could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Aida Pharmaceuticals, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.
CONTACT: Ashley Hull, +1-310-903-6908, firstname.lastname@example.org, for
Aida Pharmaceuticals, Inc.